Healthcare services company The Ensign Group (NASDAQ:ENSG). met Wall Street’s revenue expectations in Q1 CY2025, with sales up 16.1% year on year to $1.17 billion. Its non-GAAP profit of $1.52 per share was 1.9% above analysts’ consensus estimates.
Is now the time to buy ENSG? Find out in our full research report (it’s free).
The Ensign Group (ENSG) Q1 CY2025 Highlights:
- Revenue: $1.17 billion vs analyst estimates of $1.17 billion (16.1% year-on-year growth, in line)
- Adjusted EPS: $1.52 vs analyst estimates of $1.49 (1.9% beat)
- Adjusted EBITDA: $137.4 million vs analyst estimates of $133.7 million (11.7% margin, 2.8% beat)
- Operating Margin: 8.6%, in line with the same quarter last year
- Free Cash Flow Margin: 2.5%, up from 0.6% in the same quarter last year
- Sales Volumes rose 12.5% year on year (10.1% in the same quarter last year)
- Market Capitalization: $8.08 billion
StockStory’s Take
The Ensign Group’s latest quarter was shaped by continued occupancy gains and progress in both mature and newly acquired operations. Management pointed to rising skilled mix and stronger relationships with managed care networks as central to the period’s performance, citing local leadership and workforce stability as key factors. CEO Barry Port noted, “Our operators set several all-time highs during the quarter, which are only made possible by strong clinical outcomes achieved by our dedicated team of caregivers and frontline staff.”
Looking ahead, the company raised its annual earnings and revenue guidance, attributing the decision to persistent improvements in occupancy, skilled mix, and the successful integration of newly acquired facilities. Management described a disciplined approach to acquisitions and highlighted a robust pipeline, while also acknowledging broader industry challenges such as reimbursement uncertainty and staffing dynamics. CFO Suzanne Snapper emphasized, “We have confidence that we can achieve these goals” based on positive momentum and operational progress.
Key Insights from Management’s Remarks
This quarter’s results were driven by higher occupancy, improved skilled mix, and expansion into new markets. Management emphasized organic growth within existing facilities and the impact of recent acquisitions on performance.
- Occupancy and Skilled Mix Gains: Local teams achieved all-time high occupancy and notable growth in skilled patient volumes, especially in both same-store and newly acquired facilities.
- Managed Care Partnerships: Enhanced relationships with managed care organizations and Accountable Care Organizations (ACOs) led to greater patient referrals and improved payer mix, supported by a focus on clinical quality at the local level.
- Acquisition-Fueled Growth: The addition of 47 new operations since January 2024, including expansion into new states like Alabama and Alaska, contributed to a broader geographic footprint and increased bed capacity.
- Operational Efficiencies: Reductions in staff turnover and agency staffing use improved continuity of care and controlled labor costs, supporting margin stability.
- Real Estate Strategy: The company prioritized acquiring real estate assets alongside operating businesses, with its Standard Bearer Healthcare REIT subsidiary adding 13 new properties and generating stable rental revenue.
Drivers of Future Performance
Management’s outlook centers on sustaining organic growth in occupancy and skilled mix, maintaining acquisition momentum, and navigating external policy and reimbursement risks.
- Organic Portfolio Upside: The company sees significant room for operational improvements within existing facilities, aiming to drive further occupancy and skilled mix gains without relying solely on acquisitions.
- Acquisition Pipeline and Leadership: Ongoing expansion depends on a pipeline of qualified local leaders to manage new facilities, with capital available but talent as the main limiting factor.
- Regulatory and Funding Environment: Management remains closely engaged with federal and state policy developments, particularly around Medicaid reimbursement and staffing requirements, which could impact future profitability.
Top Analyst Questions
- Ben Hendrix (RBC Capital Markets): Asked how managed care contracting and value-based arrangements are influencing confidence in the guidance raise; management pointed to local relationships and clinical quality as drivers of success in these contracts.
- Ben Hendrix (RBC Capital Markets): Inquired about the company’s positioning amid policy uncertainty in Washington, especially related to Medicaid changes; CEO Barry Port detailed ongoing advocacy efforts and said the company is not a large beneficiary of Medicaid expansion populations.
- Tao Qiu (Macquarie Capital): Queried the sustainability of the current investment pace and changes in deal composition; management responded that deal flow remains strong, with an opportunistic mix between real estate and leases.
- Tao Qiu (Macquarie Capital): Sought insights on staffing constraints and whether admissions are limited by workforce shortages; management noted agency staffing has returned to near pre-pandemic levels and turnover is improving.
- A.J. Rice (UBS): Asked about competition for acquisitions and economics in new markets; management said competition is steady and success depends on local expertise, particularly as they expand in the Southeast.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) continued improvements in occupancy and skilled patient mix across mature and newly acquired operations, (2) the pace and integration of acquisitions in both established and new geographies, and (3) potential impacts from changes in Medicaid policy or reimbursement rates. Developments in workforce stability and managed care relationships will also be important for tracking operational progress.
The Ensign Group currently trades at a forward P/E ratio of 22×. Should you load up, cash out, or stay put? See for yourself in our free research report.
The Best Stocks for High-Quality Investors
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.